Introduction
============

AMP-activated protein kinase (AMPK) is an essential metabolic sensor that responds to increases in the cellular adenosine monophosphate (AMP) to adenosine triphosphate (ATP) ratio (AMP:ATP) by activating catabolic pathways for energy production. In addition to metabolic stresses, the AMPK pathway is also activated in response to various stress-related signals including infection and inflammation. A wide range of infectious diseases have been shown to trigger AMPK signaling cascades, resulting in modulation of host responses that can either enhance pathogen survival or promote host defenses in a context-dependent manner ([@B28]; [@B73]; [@B87]; [@B58]). Recent studies have revealed a diverse array of functions associated with the AMPK pathway, including regulation of host signaling, and participation in important defensive functions such as autophagy, mitochondrial biogenesis, metabolic reprogramming, and regulation of inflammation during infection ([@B87]; [@B103]). Each of these discoveries offers the potential of new therapeutic strategies capable of harnessing the AMPK pathway to combat diverse infectious diseases including human tuberculosis (TB).

*Mycobacterium tuberculosis* (Mtb) is the major causal pathogen of TB, which remains a global health problem, with a high prevalence of both multidrug-resistant and extensively drug-resistant TB ([@B116]). With approximately one third of the world's population thought to be latently infected with Mtb, there remains an urgent need for new therapeutic developmental modalities. These advances, however, remain limited by an incomplete understanding of the host-pathogen interaction due in part to the complicated lifestyle of Mtb within host cells ([@B39]; [@B21]). Mtb has a unique waxy coating on its cell wall comprised primarily of mycolic acids, a unique adaptation which enables survival within host cells ([@B15]). In addition to its cell wall, Mtb has evolved multiple strategies to evade both innate and adaptive immune defenses, enabling both persistent infection and even active replication within the human host ([@B39]), though the exact mechanisms underlying this survival remain poorly understood.

Upon Mtb infection, a variety of mycobacterial components including protein antigens and lipids trigger a series of innate inflammatory responses in host macrophages, though these pathogens can often resist these responses and escape from immune clearance ([@B21]). Despite this, excessive inflammatory responses by the host can often lead to unwanted pathological damage during infection ([@B12]). Since Mtb can persist within the highly lipophilic replicative niche of macrophages for most of its life cycle, an intricate interconnection between bacterial and host cellular metabolism will ultimately determine the overall picture of host-pathogen interaction ([@B39]). Autophagy, as a cell-autonomous quality control system, is a crucial process for maintaining homeostasis of the immune, inflammatory, and metabolic responses in host cells during infection ([@B19]; [@B82]). Given the clear need for overcoming drug-resistant issues, many efforts are being made to develop host-targeted therapies to combat TB and other infections.

In this review, we summarize the current literature suggesting a role for AMPK as a central mediator regulating a diverse set of biological responses including autophagic, lysosomal, and metabolic pathways in the Mtb-infected host. In addition, we analyze the regulatory mechanisms underlying the beneficial antimicrobial effects mediated by AMPK signaling during Mtb infection. Finally, we discuss the advances and technical challenges surrounding the use of AMPK-targeting small molecules as novel therapeutic strategies for the treatment of TB.

Overview of AMPK
================

AMP-activated protein kinase is a member of the serine/threonine (Ser/Thr) kinase family and is ubiquitously expressed in eukaryotic cells. AMPK monitors and senses the AMP/ADP relative to ATP to maintain an adequate energy supply by promoting catabolic pathways and/or decreasing anabolic pathways in response to stress conditions ([@B73]). Maintaining proper ATP concentrations within cells is critical for cell survival, as dysregulation of energy homeostasis can lead to a wide range of pathologies including metabolic diseases, cardiovascular diseases, and cancer ([@B35],[@B36]; [@B5]).

AMP-activated protein kinase exists as a heterotrimeric complex composed of a catalytic α subunit and two regulatory β and γ subunits ([@B36]; [@B38]; [@B73]). Furthermore, there are several isoforms for each subunit of AMPK (two for α and β subunits; three for γ subunits), which combine to form different AMPK complexes. As the catalytic subunit, the α subunit of AMPK complex is a main functional component and essential for AMPK activation through its phosphorylation of Thr172, whereas the γ subunit functions as a sensor of ADP levels and interacts with ADP ([@B76]; [@B38]; [@B73]).

AMP-activated protein kinase activation is mediated by several upstream signaling pathways, including the liver kinase B 1 (LKB1) tumor suppressor, as well as Ca^2+^/calmodulin-dependent kinase II (CaMKKII)-mediated phosphorylation of AMPK ([@B30]; [@B66]). In addition, TGF-β-activated kinase-1 (TAK1) acts as an upstream kinase for AMPK ([@B120]; [@B42]; [@B74]; [@B103]). Several lines of evidence showed a reciprocal regulation between AMPK and mTOR signaling pathways. AMPK phosphorylation leads to the inhibition of mammalian target of rapamycin (mTOR) through phosphorylation of tuberous sclerosis complex 2 (TSC2), which in turn affects both cell metabolism and growth ([@B13]; [@B41]). Another mechanism by which AMPK inhibits mTOR activity is mediated through phosphorylation of RAPTOR (regulatory-associated protein of mTOR) ([@B33]). On the other hands, mTOR signaling suppresses the activation of AMPK through p70 S6 kinase 1 (S6K1)-mediated inhibition of TAK1 ([@B121]; [@B109]). Interestingly, AMPK and its upstream kinase LKB1, as well as mammalian target of rapamycin complex 1 (mTORC1), are primarily located at the surface of the lysosome where they coordinate various homeostatic signaling pathways such as autophagy ([@B55]; [@B6]). The elaborate mechanisms that delineate the reciprocal regulation between AMPK and mTOR pathways are shown in [Figure 1](#F1){ref-type="fig"}.

![A brief summary of reciprocal regulation between AMPK and mTOR pathways. AMPK is activated by upstream signaling pathways, including LKB1, CaMKKII, and TAK1. AMPK pathway inhibits mTOR signaling, through at least two mechanisms, i.e., phosphorylation of TSC2 via Rheb, and direct phosphorylation of RAPTOR. In addition, mTOR-S6K1 signaling pathway inhibits AMPK activation through inactivation of TAK1.](fmicb-10-00520-g001){#F1}

Upon activation, AMPK functions as a signaling hub regulating a vast array of proteins, enzymes, metabolic pathways, and other signaling pathways ([@B37]; [@B73]). Through its crosstalk with various signaling mediators, AMPK serves as a key modulator under diverse physiologic conditions, including cell growth, proliferation, autophagy, mitochondrial biogenesis, stress responses, and immune regulation ([@B36]; [@B99]). In addition, AMPK activation is critically required for controlling mitochondrial biogenesis and metabolic function to promote cell survival and keep homeostasis ([@B36]; [@B129]). Under pathological condition, dysregulation of AMPK is associated with pathogenesis of various human diseases including inflammatory, metabolic, and neurodegenerative diseases ([@B93]; [@B84]; [@B110]). Indeed, numerous pathogens can modulate AMPK activity to enhance or ameliorate host protective immune responses during infection ([@B73]; [@B103]). Moreover, AMPK activity is closely associated with immunometabolic regulation during a wide range of infections ([@B64]; [@B73]). In addition to the roles described above, emerging evidence suggests that AMPK is involved in the activation of antimicrobial immunity and immunopathologic responses during mycobacterial infection through its interaction with other signaling pathways ([@B122]; [@B80]). These results, combined with other results which will be discussed in the later section of AMPK-targeting small molecules in this review, have shed the light on the development of potential therapeutics for host-directed therapy against TB and other infectious diseases. However, future studies are warranted to investigate the contribution of AMPK-targeted therapy *in vivo* and to delineate the mechanisms by which AMPK regulates innate immune responses during different stages of Mtb infection.

AMPK: Autophagy-Inducing Kinase in Mycobacterial Infection
==========================================================

Autophagy is an intracellular pathway that is crucial for maintenance of homeostasis by triggering the degradation of long-lived proteins and unnecessary intracellular components in response to a variety of stresses ([@B72]; [@B10]). Numerous studies have demonstrated a role for autophagy in a variety of biological responses including the regulation of innate and adaptive immunity, and antimicrobial responses ([@B59]; [@B72]). A full overview of the roles and mechanisms by which autophagy activates antimicrobial effector pathways and controls inflammation during mycobacterial infection has been reviewed elsewhere ([@B16], [@B17]; [@B18]; [@B75]; [@B60]; [@B82]). As an autophagy-activating kinase, AMPK is involved in the regulation of innate host defense against intracellular pathogens, including Mtb ([@B122]; [@B104]). Here, we briefly discuss autophagy and mycobacterial infection, and the role of AMPK activation in the antimicrobial response to Mtb infection.

AMPK Cross-Talk With Autophagy in Mycobacterial Infection
---------------------------------------------------------

Initiation of macroautophagy is triggered by the UNC-51-like kinase 1/2 complex \[ULK1 and ULK2, the mammalian orthologs of autophagy-related 1 (Atg1)\] ([@B34]; [@B70]) and serves as an important downstream effector. The resulting effector molecules are in turn regulated by the coordinated function of AMPK and mTORC1 ([Figure 2](#F2){ref-type="fig"}) ([@B49]). Activated AMPK induces the phosphorylation of serine residues S317, S555, and S777 of ULK1, a mammalian autophagy-initiating kinase, which plays an important role in starvation-induced autophagy ([@B3]; [@B49]; [@B118]). Indeed, ULK1 has several phosphorylation sites relevant to this process, including mTORC1-mediated phosphorylation of ULK1, which disrupts the association between ULK1 and AMPK ([@B49]). Previous studies showed that Mtb infection of macrophages by the mTOR/70 kDa ribosomal S6 kinase 1 (S6K1) pathway serves as an inhibitor of host autophagy, as well as a driver of inflammatory responses ([@B123], [@B122]). By contrast, induction of AMPK activation by AICAR resulted in phosphorylation of ULK1 at Ser317 and Ser777, thereby promoting host cell autophagy and antimicrobial responses in both *in vitro* macrophage assays and *in vivo* ([@B122]). These data suggest that Mtb infection drives activation of mTOR signaling, with the presumed benefits of nutrient support and immunologic shelter via lipid body formation in host macrophages. However, AMPK activation by autophagy-inducing agents may counteract the pathogen strategy and redirect intracellular defenses toward catabolism in the form of increased lysosomal activation. Given the well-established function of AMPK in autophagy activation and negative regulation of mTOR pathways, AMPK might represent a promising target of host-directed therapy against TB ([@B124]; [@B104]).

![AMPK-mTOR signaling pathways during Mtb infection. During infection, Mtb can activate mTOR pathway to enhance lipid body formation and ULK1 inhibition. AMPK activation, which is induced by AMP/ATP ratio, LKB1, intracellular calcium influx, as well as IRGM, is required for autophagy activation through ULK1 phosphorylation at Ser317/555/777. Either adaptive (Th1 cytokine IFN-γ) or innate (NOD2) signaling can induce IRGM activation, which is required for autophagy activation. AMPK-mediated Beclin-1 phosphorylation also activates autophagy to enhance phagosomal maturation. AMPK and mTOR pathways reciprocally inhibit each other to regulate autophagy, metabolism, and inflammatory responses in host cells during Mtb infection. AMPK-mediated TFEB activation leads to lysosomal activation and fatty acid β-oxidation to suppress lipid body formation. Mtb-mediated Akt phosphorylation can inhibit Foxo3A activation, which is also required for autophagy activation in the host cells.](fmicb-10-00520-g002){#F2}

The IFN-γ-inducible GTPase IRGM is an autophagy protein associated with Crohn's disease and TB ([@B4]). Activation of this protein is essential for phagosomal maturation and elimination of Mtb in murine and human macrophages ([@B62]; [@B32]; [@B105]; [@B106]). Nevertheless, how the IRGM GTPase exerts its innate effector function during intracellular infection remains poorly understood. One pathway that has been implicated in innate immunity involves IRGM-mediated stabilization of intracellular AMPK (total and activated forms of AMPK), which in turn helps preserve levels of ULK1, ATG14, and ATG16L1, thereby enabling formation of the autophagic machinery ([@B8]). In addition, AMPK promotes autophagy via Beclin-1 phosphorylation at Thr388, which is required for Beclin-1 interaction with phosphatidylinositol 3-kinase catalytic subunit type 3 (PIK3C3) and autophagy-related 14 (ATG14) ([@B128]). Given the previous findings of NOD2-mediated IRGM ubiquitination and activation ([@B8]), this IRGM-AMPK signaling pathway may serve as a bridge connecting innate immune signaling with functional activation of the autophagic machinery in response to mycobacterial infection.

AMPK and Lysosomal Function in Mycobacterial Infection
------------------------------------------------------

Transcription factor (TF) EB, a master gene for lysosomal biogenesis, is an essential upstream regulator of autophagy, serving as a transcriptional activator of numerous autophagy and lysosomal related genes ([@B98]). Under basal conditions, TFEB is suppressed by the action of cathepsin B-mediated cleavage of the calcium channel MCOLN1 in lysosomes, thus controlling the number of autophagosomes and lysosomes ([@B65]). TFEB phosphorylation by the mTORC1 kinase retains TFEB in its inactivated state in the cytosol ([@B68]; [@B92]). However, recruitment of AMPK leads to the suppression of mTORC1 activity, thereby activating TFEB ([Figure 2](#F2){ref-type="fig"}), which is then transported into the nucleus where it activates transcription of the autophagic and lysosomal machinery and can even activate ULK1 in cases of *Francisella novicida* infection ([@B88]). In addition, induction of phagocytosis via the Fc receptor can itself increase the expression of lysosomal proteins through nuclear translocation and activation of TFEB, serving as an essential step for lysosomal degradation of phagocytosed bacteria ([@B29]). A recent study showed that TRIM16, an interacting protein of galectin-3, played a protective role in controlling Mtb infection through cooperation with core autophagic machinery in autophagic responses, and simultaneously affected TFEB activation ([@B7]).

Previous studies showed a stronger activation of mTOR kinase phosphorylation, relative to AMPK, in macrophages following Mtb infection in a time-dependent manner ([@B122]). Data indicating that cytosolic Mtb co-localizes with the components of autophagic machinery, i.e., p62 and LC3, was evident in only 30% of total Mtb phagosomes ([@B115]), providing evidence for the idea that the majority of intracellular Mtb might stop the activation of xenophagy due to a downregulation of TFEB nuclear translocation by mTOR activation during infection. In addition, Mtb can induce diverse innate immune signaling responses which converge on the NF-κB pathway and manipulate the host protective immune responses ([@B97]; [@B108]). Mtb infection enhances the levels of microRNA (miRNA)-33 and miR-33^∗^ via the NF-κB pathway to inhibit autophagy, lysosomal function, and fatty acid β-oxidation. In this setting, AMPK activation appears to be crucial for the induction of TFEB, which promoted lipid catabolism as well as xenophagy against Mtb ([@B81]).

As the role of AMPK as a key modulator of TFEB-mediated lysosomal activation becomes clearer, the mechanisms by which AMPK activates autolysosomal function in the context of host defense against mycobacterial infection have garnered greater attention. Our recent study highlighted the importance of TFEB activation in antimicrobial responses along with the dampening pathologic inflammation during Mtb infection ([@B52]). Importantly, the activation of peroxisome proliferator-activated receptor (PPAR)-α, a nuclear receptor that interacts with AMPK during metabolism ([@B27]), was found to enhance lysosomal biogenesis and function via TFEB, as well as protective antimicrobial responses against Mtb ([@B52]).

A recent study showed that lysosomal damage inhibits mTOR kinase activity by galectin-8 interaction with the mTOR apparatus ([@B47]). However, galectin-9 activates AMPK signaling in response to lysosomal injury, and the galectin-based signal-transduction system plays a critical role in the activation of autophagy and host defense against Mtb ([@B47]). Further investigations in the mechanisms by which the host integrates galectin-based signaling networks during persistent infection with Mtb will be important for the development of anti-mycobacterial therapies capable of providing protective immunity against infection.

The autophagosomal proteins soluble *N*-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) and ATG14 are important in autophagosome--lysosome fusion ([@B43]; [@B20]). Earlier studies showed that mannose-capped lipoarabinomannan of Mtb was an inhibitor of phagosomal acidification through a SNARE alteration, thus contributing to virulence during Mtb infection ([@B25]). The autophagy protein Irgm1 has been shown to exert antimicrobial effects against mycobacterial infection through the recruitment and subsequent accumulation of PtdIns(3,4)P~2~ and PtdIns(3,4,5)P~3~ to phagosomal membranes. These proteins modify the ability of Irgm1 to enhance immunity to Mtb phagosomes via its interaction with SNARE effectors ([@B113]). Despite these observations, few studies have sought to examine the role of AMPK in the modulation of SNARE as part of the autophagic flux observed during mycobacterial infection. A future challenge will be to determine the distinct role of AMPK on the SNARE system and how it integrates complex signaling networks into lysosomal homeostasis during mycobacterial infection.

Roles of AMPK in Immunometabolism During Mycobacterial Infection
================================================================

In response to inflammation, innate immune cells undergo an immunometabolic shift from enhanced aerobic glycolysis in early phases to high oxidative metabolism in later stages, which is often the result of AMPK activation ([@B77]; [@B48]). In addition to autophagy regulation, AMPK plays a crucial regulator of mitochondrial function and metabolism, through sensing the intracellular energy levels in innate immune cells ([@B117]). Here we briefly discuss the immunometabolism and its control by AMPK signaling pathways in innate immune cells in terms of mycobacterial infection.

Overview of Immunometabolism in Innate Immune Cells
---------------------------------------------------

Recent studies have highlighted on the metabolic reprogramming in various immune cells. In particular, macrophages and dendritic cells (DCs) are principal innate immune cells that participate in the initiation and resolution of inflammatory responses during infection ([@B77]; [@B48]; [@B117]). In M1 macrophages and DCs, the source of energy is mainly provided by upregulation of aerobic glycolysis, although less efficient in the ATP production. Utilizing glycolysis, M1 macrophages and DCs can respond to more rapidly than oxidative phosphorylation (OXPHOS), to meet the energy request for the generation of inflammatory responses and biosynthetic precursor molecules in the initial phase of innate immune responses ([@B26]; [@B117]). M1 macrophages show the metabolic characteristics of broken Krebs cycle and decreased fatty acid oxidation (FAO) and OXPHOS ([@B26]; [@B48]; [@B79]; [@B117]). In this process, the increase of certain metabolites such as succinate and citrate, byproducts of fragmented Krebs cycle, act as signaling molecules that modulate inflammatory pathways in M1 macrophages ([@B26]; [@B48]; [@B79]; [@B117]). Recent studies also revealed that specific metabolic pathways and metabolites such as itaconate are crucial for anti-mycobacterial effects ([@B71]; [@B117]).

In DCs, TLR stimulation facilitates a metabolic shift to aerobic glycolysis that is linked to DC maturation and functional activation ([@B56]; [@B14]; [@B22]; [@B79]). Importantly, the metabolic shift in DCs leads to the upregulation of fatty acid synthesis through pathways of recharging NADPH and utilization of citrate and isocitrate to efficiently accommodate cellular demand for protein synthesis during inflammation ([@B56]; [@B14]; [@B22]). Glycolysis is strongly upregulated in another inflammatory cells, Th17 cells, and functioned in the metabolic checkpoint regulation in T cell lineage differentiation ([@B101]; [@B78]). In murine M2 macrophages the Krebs cycle and OXPHOS are intact and functioning, and generate metabolic intermediates for protein glycosylation ([@B26]; [@B46]; [@B79]; [@B117]). It is now being recognized that immunoregulatory cells including M2 macrophages and regulatory T cells have a reliance on OXPHOS-dependent metabolism for their function ([@B117]). Taken together, [Figure 3](#F3){ref-type="fig"} summarizes a brief overview of immunometabolism in M1 and M2 macrophages, and DCs.

![Summary of the immunometabolism in macrophages and DCs. In M1 and DCs, LPS stimulation leads to the upregulation of aerobic glycolysis, and altered TCA cycle with aberrant increase of several metabolic intermediates including succinate, citrate, and itaconate, which act as signaling and effector molecules in inflammatory responses and infection. In DCs, metabolic reprogramming results in the increased fatty acid synthesis through recharging NADPH and utilization of citrate. In M2 macrophages, the Krebs cycle and OXPHOS are intact to drive immunosuppression and the resolution of inflammation.](fmicb-10-00520-g003){#F3}

In innate immune cells, the pro-inflammatory signals inhibit AMPK activation in the initial stage of inflammation and negatively regulates the NF-κB signaling ([@B94]). Since AMPK senses the energy status in the cells undergoing inflammatory responses, its activation drives catabolic pathways such as FAO and OXPHOS, and simultaneously inhibits mTOR signaling and inflammatory pathways ([@B77]; [@B48]; [@B1]; [@B117]). AMPK signaling, balanced with mTOR, appears to be a key immunometabolic regulator capable of influencing immune cell differentiation and is reinforced by autophagic function ([@B1]; [@B91]). This review will focus on the role of AMPK in innate immune cell function during Mtb infection.

Warburg Effect Mediated by HIF-1α During Mycobacterial Infection
----------------------------------------------------------------

Upon Mtb infection, the host immune responses are often confronted with the Warburg effect, a process through which immune cells efficiently meet cellular biosynthetic capacity to activate inflammatory responses and antimicrobial molecules ([@B100]; [@B91]). In this process, Mtb pathogenicity may be attributable to its perturbation of the Warburg effect, enabling escape from M1 macrophage polarization and Th1 protective immunity, to replicate and persist inside host cells ([Figure 4](#F4){ref-type="fig"}) ([@B100]).

![Regulation of immunometabolism in macrophages infected with Mtb. In early phase of Mtb infection, mTOR kinase activation leads to the immunometabolic shift to M1 macrophages that generate pro-inflammatory cytokine by activation of NF-κB and HIF1α signaling. M1-like macrophages increase glycolysis and inflammation through HIF1α and NF-κB signaling pathways. In later phase of infection, M2-like macrophages increase mitochondrial oxidative phosphorylation through AMPK activation. AMPK pathway enhances PGC1α and ERRα activity that is required for autophagy activation through transcriptional and translational regulation. Although the mTOR-HIF1α pathway is essential for initial control of Mtb growth, excessive induction of inflammation seems to be harmful to the host. Similarly, the prolonged activation of AMPK signaling to drive M2-like macrophages may result in the immunosuppression that is detrimental to eradicate intracellular mycobacteria.](fmicb-10-00520-g004){#F4}

Mtb infection of macrophages or peripheral blood mononuclear cells induces strong activation of the mTOR/S6K1 and Akt signaling pathways to modulate host autophagy and metabolic processes ([@B123], [@B122]; [@B57]). The signaling pathways involving mTOR and Akt play a crucial role in the glycolytic shift in macrophages during infection ([@B69]). As part of the bioenergetics shift to the Warburg effect, hypoxia-inducible factor (HIF)-1α, a downstream target of mTORC1 ([@B91]), promotes transcription of inflammatory genes as well as transcripts involved in aerobic glycolysis and *de novo* lipid synthesis in immune cells ([@B112]; [@B48]; [@B91]). A recent study using an experimental TB model suggested a dual role of HIF-1α; i.e., a protective role during early stages of the disease, but detrimental in later phage of TB ([@B2]). HIF-1α-mediated Warburg effect likely contributes to protective immune responses at the site of infection early in disease but may lead to injurious necrosis and pathology during a prolonged infection ([Figure 4](#F4){ref-type="fig"}).

AMPK-Mediated M1/M2 Regulation and Iron Homeostasis During Mtb Infection
------------------------------------------------------------------------

Given the crucial function of AMPK in metabolic regulation, AMPK is often regarded as a master regulator of immunometabolism in immune cells, through orchestrating mitochondrial biogenesis, OXPHOS, and M2 macrophage differentiation ([Figure 4](#F4){ref-type="fig"}) ([@B79]; [@B31]). In M2 macrophages, the generation of proinflammatory cytokines decreased in response to Mtb infection, whereas the anti-inflammatory cytokines and growth factors are unaffected, maintaining normal function and tissue repair ([@B31]). Previous studies have largely found that M2 macrophages exhibit broad anti-inflammatory responses during Mtb infection, enabling a more permissive environment for intracellular mycobacteria growth ([@B95]; [@B61]). By contrast, this type of immune response may also be advantageous to the host, protecting against potentially harmful immunopathology including extensive tissue damage ([@B85]). Thus, AMPK may play as a checkpoint regulator of immunometabolism to tilt the balance to favor the increased host defense during Mtb infection.

A recent study has shown that ferritin heavy chain, a major factor regulating the preservation of iron in the host, is a critical factor in protective immunity, serving to ameliorate potentially pathologic inflammation caused by excessive mitochondrial activity and oxidative phosphorylation in host cells ([@B89]). Given previous findings that AMPK is an important upstream regulator of ferritin heavy chain transcription ([@B44]), further research into the role of AMPK in iron homeostasis and its effects on inflammation and immune responses against Mtb infection are warranted.

AMPK-Induced Downstream Effectors That Coordinate Mitochondrial Function and Host Defense
-----------------------------------------------------------------------------------------

In addition to these studies, previous work from our laboratory reported that AMPK activation resulted in increased mitochondrial biogenesis through peroxisome proliferator-activated receptor-γ coactivator (PGC)-1α, a downstream molecule of AMPK signaling ([@B122]). Importantly, PGC1α is critically involved in the antimicrobial immune defense and phagosomal maturation against Mtb ([@B122]). A more recent study revealed that estrogen-related receptor (ERR)-α, which is closely associated with PGC1α, was required for autophagy activation and host defense to Mtb infection ([@B53]). ERR-α works as an essential autophagy regulator by transcriptional and post-translational regulation of autophagy genes ([@B53]). Although ERR-α is an orphan nuclear receptor, for which the physiological ligands have not been known, ERR-α expression was upregulated by either AMPK or sirtuin 1 (SIRT1) activator ([@B53]). There is a mutual regulation between ERR-α and SIRT1 to enhance innate immune responses and ameliorate inflammation ([@B126]; [@B53]). Treatment of Mtb-infected cells with SIRT1 activator resveratrol increased co-localization of Mtb phagosomes with lysosomes, suggesting an improved phagosomal maturation in macrophages ([@B53]). In addition, a recent study showed that SIRT1 is required for dampening immunopathogenesis of TB, suggesting a beneficial role for SIRT1 activation in host protection ([@B9]). Moreover, AMPK activation is linked to mitochondrial biogenesis through activation of PGC1α and SIRT1 ([@B130]; [@B67]; [@B119]; [@B111]). Nevertheless, more work is necessary to determine how PGC1α/ERRα/SIRT1 mediates anti-TB immunity, and whether AMPK-induced mitochondrial biogenesis itself serves to limit intracellular mycobacterial survival.

Small Molecules That Modulate AMPK to Regulate Host Defense against Mtb Infection
=================================================================================

Given the opposing roles of AMPK and mTOR, significant attention has been given to small molecules and other compounds capable of activating AMPK or inhibiting mTOR as a potential therapeutic strategy for the host-directed therapy against TB ([@B24]; [@B96]; [@B104]). Earlier studies suggest that pharmacologic inhibition of mTOR by rapamycin promotes phagosomal colocalization with autophagosomes and restriction of intracellular mycobacterial growth in macrophages ([@B32]). Rapamycin is well-known for immunosuppressive activity to be useful for prevention of organ transplantation rejection ([@B83]). Several mTOR inhibitors including everolimus are being used in the treatment of various types of cancers due to the inhibitory function in cell proliferation ([@B86]; [@B54]). Although there might be a possibility of mTOR inhibitors as candidates of host-directed therapy against multi-drug-resistance (MDR)- or extensively drug-resistance (XDR)-TB, the impact for mTOR inhibitor-based adjunctive therapy in the context of TB remains to be determined, because of serious side effects such as hyperglycemia and immunosuppression ([@B104]).

Targeting AMPK in mycobacterial infection appears to promote anti-mycobacterial effects and inhibit much of the exaggerated inflammatory responses associated with disease pathology. Indeed, numerous autophagy-activating agents appear to work by triggering the AMPK pathway, making this protein a useful target for modulating the antimicrobial response to Mtb ([@B40]; [@B23]). In human monocytes/macrophages, vitamin D induces antimicrobial effects through autophagy activation via cathelicidin expression ([@B127]). Four-phenylbutyrate and vitamin D-induced autophagy was dependent on the endogenous antimicrobial protein LL-37, of which LL-37-mediated autophagy required activation of the AMPK pathway ([@B90]). In addition, activation of functional vitamin D receptor signaling by the mycobacterial antigen LpqH was shown to be dependent on the AMPK-mediated p38 MAPK pathway to produce cathelicidin LL-37 for antimicrobial responses against Mtb infection ([@B102]). Furthermore, AMPK activator AICAR showed beneficial effects through the enhancement of bacterial colocalization with autophagosomes to enhance phagosomal maturation and antimicrobial responses against Mtb infection ([@B122]). AICAR treatment of macrophages led to an induction of DRAM2, an autophagy protein targeted by miR144^∗^ in human monocytes/macrophages, to enhance host defense to Mtb ([@B50]). A recent study also showed that ohmyungsamycins, a class of newly identified cyclic peptides, activated autophagy and antimicrobial effects, and attenuated inflammatory responses against Mtb through AMPK pathway activation ([@B51]).

Notably, metformin, the well-known antidiabetic drug and AMPK activator, was shown to be beneficial for host protection, even in cases of drug-resistant Mtb ([@B107]). As a treatment for Mtb, AMPK activation is required for metformin-mediated reduction of Mtb growth in macrophages. In addition, metformin treatment was shown to ameliorate chronic inflammation and lung pathology and improved bacterial control in a mouse model of infection. In TB patients, metformin therapy was associated with improvements in several clinical parameters, including disease severity ([@B107]). The dual role for metformin in diabetes and Mtb infection is important, as diabetes itself is an independent risk factor for active TB, and is associated with TB severity ([@B45]); TB may lead to glucose intolerance, with TB patients often experiencing difficulty in glycemic control ([@B125]). While still unproven, targeting AMPK represents an exciting new treatment option for TB combined with diabetes, with strong efficacy in animal models of TB driven by its support of healthy mitochondria, reduced inflammation, and regulation of autophagy and apoptosis ([@B63]). Studies involving the functions of AMPK in mycobacterial infection is summarized in [Table 1](#T1){ref-type="table"}. More comprehensive studies are warranted to explore the prospect of targeting AMPK in patients with both diabetes and TB.

###### 

Summary of studies employing the functions of AMPK in mycobacterial infection.

  Effectors targeting AMPK   Mycobacterial strains                          Observed autophagy/immunometabolism outcome                                                                                                                                                                                                                                                                 Observed antimycobacterial effects                                                                                                                                                                                                                                                                                                     Type of cells                                               Type of animal, human subjects                                                          Reference
  -------------------------- ---------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------- --------------------------------------------------------------------------------------- -----------
  AICAR                      •M. tuberculosis•M. marinum•M. bovis BCG       •↑ AMPK activation and antibacterial autophagy against *M. tuberculosis* in AICAR-treated cells•↑ Oxidative phosphorylation, mitochondrial ATP production, and biogenesis•↑ Transcriptional activation of multiple autophagy-related genes                                                                  •↓ Intracellular survival in *M. tuberculosis*-infected cells•↓ Mortality and bacterial burden in *M. marinum*-infected Drosophila melanogaster•↓ CFU of M. bovis BCG in the spleen of Atg7fl/fl LysM-Cre- mice, but not Atg7fl/fl LysM-Cre+ mice (about 1 log reduction)                                                              •BMDM•Raw 264.7•THP-1                                       •Atg7fl/fl LysM-Cre+ mice•Spargel mutant Drosophila                                     [@B122]
  LpqH                       •*M. tuberculosis* H37Rv                       •↑ Antibacterial autophagy in LpqH-treated cells•↑ C/EBP-β-dependent induction of Cyp27b1 hydroxylase•↑ Cathelicidin expression•↑ Intracellular Ca^2+^/AMPK/p38 MAPK signaling pathway                                                                                                                      •↓Survival rate of intracellular Mtb by 35-42% in LpqH-treated human monocytes                                                                                                                                                                                                                                                         •Monocytes•Human MDM•THP-1                                                                                                                          [@B102]
  Phenylbutyrate             •*M. tuberculosis* H37Rv                       •↑ LL-37 expression and autophagy activation through Intracellular Ca^2+^, AMPK, and PtdIns3K signaling pathway•↑ Expression of the autophagy-related genes BECN1 and ATG5•↑ Colocalization of LC3-II and LL-37 in the autophagosome                                                                        •↓ Intracellular Mtb growth in phenylbutyrate-treated human MDM (40--60% growth inhibition, *P* = 0.002)                                                                                                                                                                                                                               •Monocytes•Human MDM•THP-1                                                                                                                          [@B90]
  miR-33 miR-33^∗^           •*M. tuberculosis* H37Rv                       •↑ lipid body formation in Mtb-infected macrophages•↓ fatty acid oxidation in Mtb-infected macrophages•↓ induction of autophagy via the regulation of autophagy gene expression•↓ Mtb killing *in vitro* BMDM and *in vivo* mice model•↓ expression of AMPKα and downstream transcription factors           •↑ Dead or metabolically inactive Mtb by inhibition of miR-33 and miR-33^∗^ in peritoneal macrophage and BMDM (the dual Immunofluorescence viability assay and CFU assay)•↓ Bacterial counts in the lung of hematopoietic miR-33 deficient mice on day 53 post-infection                                                               •BMDM•Alveolar Macrophages•THP-1•HEK293 cells               •Prkab1-/- mice•Atg16fl/fl LysM-Cre+ mice•Mir33-/- mice                                 [@B81]
  miR-144                    •*M. tuberculosis* H37Rv•Mtb-ERFP              •↓ induction of autophagy via post-transcriptional regulation of DRAM2•↑ Mtb infection, ↓ activators of the AMPK pathway such as AICAR and vitamin D3                                                                                                                                                       •Intracellular Mtb growth: Human MDMs transfected with miR-144 inhibitor (↓) or miR-144 mimic (↓)                                                                                                                                                                                                                                      •Human PBMC•Human MDM•THP-1•HEK293 cells                    •Lung and lymph node tissue from TB patients                                            [@B50]
  Ohmyungsamycin A and B     •*M. tuberculosis* H37Rv•Mtb-ERFP•M. marinum   •↑ killing of mycobacteria *in vitro* macrophages and *in vivo D. melanogaster* infection model•↑ Antibacterial autophagy and Mtb phagosome maturation via AMPK signaling pathway                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                                                            •↓ Mtb-induced inflammatory responses via AMPK signaling                                                                                                                                                                                                                                                    •Evaluation of antibacterial properties against Mtb: MIC50 values for OMS-A and --B were 57 nM and 117 nM, respectively (REMA method), ↓ intracellular Mtb growth in BMDMs (CFU assay)•↓ Mortality and bacterial burden in *M. marinum*-infected *Drosophila melanogaster*                                                             •BMDM•Human MDM                                             •*Atg7*^fl^/^fl^LysM-Cre+ mice•*Atg7* mutant *Drosophila*                               [@B51]
  Galectin 8 and 9           •*M. tuberculosis* Erdman                      •↓ mTOR signaling by Galectin 8 via interaction the Ragulator-Rag SLC38A9 system•↑ AMPK signaling by Galectin 9 through the engagement of TAK1•↑ Autophagy and antimicrobial host defense against Mtb                                                                                                       •↑ Susceptibility in Mtb Erdman-infected Gal8 KO mice, as compared to WT littermates                                                                                                                                                                                                                                                   •Human MDM•BMDM•THP-1•HEK293 cells•HeLa cells               •*Atg5*^fl^/^fl^ LysM-Cre+ mice•Gal8 *Atg5*^fl^/^fl^ LysM-Cre+ mice                     [@B47]
  Metformin                  •*M. tuberculosis* H37Rv•*M. bovis* BCG        •↓ Intracellular growth of Mtb by mitochondrial ROS generation•↑ Efficacy of anti-TB drugs in Mtb-infected mice•↓ Tissue pathology, ↑Immune responses in Mtb-infected mice•↓ Inflammatory responses in Mtb-infected lung and spleen cells•↑ Clinical outcome in TB patients with type 2 diabetes mellitus   •↓ Intracellular Mtb growth in Metformin-treated human MDM in a dose and time-dependent manner (CFU assay)•↓ Intracellular survival of MDR strains of Mtb in THP-1 cells•↓ Bacterial load in the lungs and spleens of Mtb-infected mice with metformin monotherapy (250 or 500 mg/kg) or combined therapy (isoniazid of ethionamide)   •Human MDM•THP-1•Murine spleen and lung cells•Murine BMDC   •C57BL/6 mice•Evaluation of clinical outcome in patients from TB and diabetic cohorts   [@B107]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

AICAR, AMP-mimetic 5-aminoimidazole-4-carboxamide-1- β-D-ribofuranoside; BMDM, bone marrow-derived macrophages; Cyp27b1, 25-hydroxycholecalciferol-1 α-hydroxylase; C/EBP, CCAAT/enhancer-binding protein; MAPK, mitogen-activated protein kinase; MDM, monocyte-derived macrophage; PtdIns3K, phosphatidylinositol 3-kinase; BECN1, Beclin 1, autophagy related; ATG, autophagy related gene; ERFP, enhanced red fluorescent protein; DRAM2, DNA damage-regulated autophagy modulator 2; PBMC, peripheral blood mononuclear cell; BMDC, Bone marrow-derived dendritic cells; MDR, multi-drug-resistance; ↑, increase; ↓, decrease.

Finally, it should be noted that AMPK has been shown to drive immunopathology through the production of neutrophil MMP-8 ([@B80]). In addition, there is evidence of potential side effects associated with AMPK modulators ([@B11]; [@B114]). Studies employing the role of AMPK in mycobacterial infection are summarized in [Table 1](#T1){ref-type="table"}. Future development of new therapeutics targeting AMPK should consider the crosstalk of this kinase with other essential signaling pathways to achieve acceptable efficacy and safety while minimizing unwanted side effects during TB treatment.

Conclusion
==========

Since its discovery as a pivotal regulator of intracellular bioenergetics, AMPK has emerged as a central coordinator of a variety of biological responses, including autophagy, inflammation, and metabolic reprogramming during mycobacterial infection ([@B100]; [@B91]). The functions of AMPK are diametrically opposed by those of mTOR, and the balance of the activation of both kinases is reflected in the signaling pathways that converge on host defense in host cells against Mtb infection ([@B122]). AMPK promotes the induction and maturation of autophagy in response to infectious stresses and activates the transcriptional factor TFEB, which targets specific signaling modules for lysosomal function and fatty acid β-oxidation ([@B81]). AMPK-mediated autophagy activation provides a cell-autonomous defense framework, which is required for enhancement of phagosomal acidification and restriction of intracellular parasites. In addition, AMPK signaling is tightly coupled to the attenuation of pathologic inflammation, which can be harmful to the host during prolonged infection with Mtb.

Understanding how AMPK-mTOR signaling functions in response to infectious threats, and how these pathways orchestrate immunometabolic responses is essential for proper control of infectious diseases. Although AMPK activation appears to be involved in the host protection to Mtb infection through downstream regulators including PGC-1α, ERRα, SIRT1, and PPARα, little is known about the full picture of AMPK-induced effector pathways. Many questions remain unanswered, including the mechanisms by which host defenses and pathology are controlled over the course of infection, and the nature of key players that participate in the control of metabolic shifts during TB. While AMPK is well established as a central regulator of innate effector networks, a better understanding of how AMPK orchestrates this complicated host-pathogen response will be necessary for the development of new therapeutic approaches for TB. Thus, a challenge for the future studies involves coordinating a dedicated mechanism of AMPK-targeted effector pathways that integrate the antibacterial autophagy, controlling pathologic inflammation, mitochondrial biogenesis, and immunometabolism during infection.
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